Abstract 2329P
Background
Although it is an important biomarker in oncology, Ki-67 immunohistochemistry analysis has yet to be standardized. Working groups have provided guidelines for Ki-67 scoring in different cancer types to limit pathologist’s variability. Digital analysis solutions to assist scoring with image analysis or AI have recently emerged in the evaluation of Ki-67 as rapid and robust solutions. In this context, we compared the results of Ki-67 scoring performed with Aiforia® (AI platform) and Halo® (image analysis supervised software) against two independent pathologists on solid tumors.
Methods
We stained 192 tumors of various origins including breast and prostate with Ki-67 (clone 30-9). Pathologists were trained following the International Ki-67 Working Group recommendations and scored tissues accordingly. Based on deep learning, Aiforia was able to automatically score Ki-67 positive tumor cells within minutes. The random forest classifier from Halo software was used to separate the image into tumor, non-tumor and background. After cell segmentation, Ki-67 positivity was assessed by thresholding.
Results
Our study shows a very high consistency of results obtained for Ki-67 scoring between the image analysis softwares, Aiforia and Halo (r2=0.94), on all solid tumors. The correlation obtained between the two pathologists was weaker (r2=0.8), despite the training and guidelines, but remains within an acceptable range. Of the 18 types of primary tumors analyzed, only 2 (thyroid and stomach) showed correlations of less than 0.75 between the image analysis softwares with inter-pathologists' correlation still high (0.73 and 0.86). Depending on the organ, there were significant variations between pathologists, whereas the scores obtained with the image analysis softwares remain very close. For example, with prostate (n=8), a 0.81 correlation for Ki-67 scores between Aiforia and Halo was found while the inter-pathologists' correlation was 0.68.
Conclusions
This work shows that AI based image analysis tools such as Aiforia and image analysis supervised software provide valuable assistance in IHC based clinical analysis, drastically reducing inter-pathologist variability or as an arbitration tool in Ki-67 scoring of solid tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2222P - Frequent TERT gains in metastatic papillary thyroid carcinoma
Presenter: Sara Gil
Session: Poster session 16
2223P - Next-generation sequencing enables identification of RET rearrangements in papillary thyroid cancer
Presenter: Sergi Clavé
Session: Poster session 16
2224P - Identifying prognostic factors in patients with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) treated with tyrosine kinase inhibitors (TKI): Data from REGETNE registry
Presenter: Maria Victoria San Roman Gil
Session: Poster session 16
2225P - FOX1 (rs965513), NKX2-1 (rs944289) and BRAF (V600E) gene mutations and their role in development of papillary thyroid cancer
Presenter: Darko Katalinic
Session: Poster session 16
2226P - Survival benefit of radioiodine therapy (RAI) in papillary thyroid cancer variants (PTCV): A SEER analysis
Presenter: Sakhr Alshwayyat
Session: Poster session 16
2227P - The efficacy and safety of lenvatinib in neoadjuvant therapy in patients with locally advanced thyroid cancer: A single-arm phase II clinical trial
Presenter: Jianhong Yu
Session: Poster session 16
2228P - Long-term clinical outcomes of Lenvatinib in patients with differentiated thyroid cancer: Results from the real-world practice of a single institution
Presenter: Ryutaro Onaga
Session: Poster session 16
2229P - Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: Data from LIBRETTO-001
Presenter: Lori Wirth
Session: Poster session 16
2323P - Multi-omic spatial phenotyping of the NSCLC tumour microenvironment for the development of a spatial score associated with immunotherapy resistance
Presenter: Arutha Kulasinghe
Session: Poster session 16
2324P - Trametinib and PD-1 combined blockade impairs tumor growth and improves survival of KRAS-mutant lung cancer through Id1 downregulation
Presenter: Ander Puyalto
Session: Poster session 16